Antifibrinolytic agents in off-pump cardiac surgery: analysis of blood loss, safety and cost-effectiveness

Abstract

Authors compare in prospective, randomized, double-blind study hemostatic effects of fibrinolytic inhibitors (tranexamic acid, aprotinin) vs. placebo in off-pump coronary artery bypass surgery and evaluate an impact of this therapy on cost-effectiveness. Both tranexamic acid and aprotinin seem to be similarly effective in the reduction of postoperative blood loss.

Tranexamic acid appears to be cost-effective and safe alternative to aprotinin.

Keywords

• antifibrinolytic agents
• off-pump cardiac surgery
• blood loss
• safety
• cost-effectiveness